Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 4,314 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 4,314 shares of the firm’s stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $20.32, for a total value of $87,660.48. Following the completion of the sale, the president directly owned 1,087,060 shares in the company, valued at approximately $22,089,059.20. This represents a 0.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Arcus Biosciences Trading Up 3.1%

Shares of RCUS stock opened at $20.33 on Tuesday. The stock’s fifty day moving average price is $14.15 and its two-hundred day moving average price is $10.86. The company has a market cap of $2.20 billion, a PE ratio of -5.91 and a beta of 0.90. Arcus Biosciences, Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $22.11. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.06. The firm had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The company’s revenue was down 45.8% compared to the same quarter last year. During the same quarter last year, the business posted ($1.00) EPS. Equities analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RCUS has been the topic of several recent research reports. The Goldman Sachs Group raised their price objective on Arcus Biosciences from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday. HC Wainwright raised their price objective on Arcus Biosciences from $24.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Truist Financial reissued a “buy” rating and set a $39.00 price objective (up previously from $32.00) on shares of Arcus Biosciences in a report on Tuesday, October 7th. Wedbush set a $35.00 price objective on Arcus Biosciences and gave the company an “outperform” rating in a report on Wednesday, October 29th. Finally, Citigroup raised their price objective on Arcus Biosciences from $54.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $28.44.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Gilead Sciences Inc. raised its position in Arcus Biosciences by 4.5% during the 1st quarter. Gilead Sciences Inc. now owns 31,424,760 shares of the company’s stock worth $246,684,000 after purchasing an additional 1,363,636 shares during the last quarter. Vanguard Group Inc. raised its position in Arcus Biosciences by 24.1% during the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock worth $52,499,000 after purchasing an additional 1,298,584 shares during the last quarter. Woodline Partners LP raised its position in Arcus Biosciences by 45.5% during the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock worth $40,249,000 after purchasing an additional 1,603,367 shares during the last quarter. Geode Capital Management LLC raised its position in Arcus Biosciences by 14.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,596,329 shares of the company’s stock worth $12,995,000 after purchasing an additional 207,097 shares during the last quarter. Finally, Sofinnova Investments Inc. raised its position in Arcus Biosciences by 17.2% during the 2nd quarter. Sofinnova Investments Inc. now owns 1,216,016 shares of the company’s stock worth $9,898,000 after purchasing an additional 178,240 shares during the last quarter. 92.89% of the stock is owned by institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.